
 
 
 
 
 
 
 
 
   
 1. cDNA represented as a nucleotide sequence of SEQ ID NO: 2, which codes for Saxatilin, a protein derived from venom of Agkistrodon saxatilis emelianov. 
 
     
 2. Saxatilin represented as an amino acid sequence of SEQ ID NO: 1 which is derived from the cDNA of claim 1. 
 
     
 3. A process for preparing Saxatilin which comprises the steps of: gel filtration of venom collected from Agkistrodon saxatilis emelianov to obtain active fraction; and, (ii) applying the active fraction to high performance liquid chromatography to purify Saxatilin. 
 
     
 4. An expression vector pPSAX containing the cDNA of claim 1. A biologically pure culture of Pichia pastoris Y/pPSAX(KCCM-10201) which is obtained by transforming the expression vector pPSAX of claim 4 into Pichia pastoris GS115. 
 
     
 6. A process for preparing recombinant Saxatilin which comprises a step of culturing a yeast cell transformed with an expression vector containing cDNA of claim 1 to obtain recombinant Saxatilin. 
 
     
 7. The process for preparing recombinant Saxatilin of claim 6, wherein the expression vector is pPSAX. 
 
     
 8. The process for preparing recombinant Saxatilin of 35 claim 6 or claim 7, wherein the transformed yeast cell is Pichia pastoris Y/pPSAX(KCCM-10201). H:\Simeona\Keep\Speci\61848.00.doc 14/11/03 25  
 
     
 9. The process for preparing recombinant Saxatilin of claim 8, wherein the transformed yeast cell is cultured under a condition of pH 5.5 to 6.5, 25 to 35 0 C for 12 to 24 hours, harvested by centrifugation and cultured again on a medium containing 0.5 to methanol under a condition of pH 5.5 to 6.5, 25 to 35 0 C for 72 to 120 hours. The process for preparing recombinant Saxatilin of claim 8, wherein the culture containing transformed yeast cell is subjected to a hydrophobic column and high performance liquid chromatography to purify Saxatilin. 
 
     
 11. An anti-platelet agent comprising an active ingredient of Saxatilin polypeptide according to SEQ ID NO:1 and a pharmaceutically acceptable carrier. 
 
     
 12. An anti-tumor agent comprising an active ingredient of Saxatilin polypeptide according to SEQ ID NO:1 and a pharmaceutically acceptable carrier. 
 
     
 13. A method of inhibiting platelet aggregation in a subject, comprising the step of administering to the subject a therapeutically effective amount of a Saxatilin polypeptide according to SEQ ID NO:1 or a polynucleotide 25 encoding a Saxatilin polypeptide according to SEQ ID NO:2, together with a pharmaceutically acceptable carrier. 
 
     
 14. A method of inhibiting angiogenesis in a subject, comprising the step of administering to the subject a therapeutically effective amount of a Saxatilin polypeptide according to SEQ ID NO:1 or a polynucleotide encoding a Saxatilin polypeptide according to SEQ ID NO:2, together with a pharmaceutically acceptable carrier. 35 15. A method of inhibiting metastatic tumor growth in a subject, comprising the step of administering to the subject a therapeutically effective amount of a Saxatilin H:\Simeona\Keep\Speci\61848.00.doc 14/11/03 26 polypeptide according to SEQ ID NO:1 or a polynucleotide encoding a Saxatilin polypeptide according to SEQ ID NO:2, together with a pharmaceutically acceptable carrier. 
 
     
 16. Use of a Saxatilin polypeptide according to SEQ ID NO:1 or a polynucleotide encoding a Saxatilin polypeptide according to SEQ ID NO:2 in the preparation of a medicament for use in treating a condition associated with platelet aggregation. 
 
     
 17. Use of a Saxatilin polypeptide according to SEQ ID NO:1 or a polynucleotide encoding a Saxatilin polypeptide according to SEQ ID NO:2 in the preparation of a medicament for use in treating a condition associated with angiogenesis. 
 
     
 18. Use of a Saxatilin polypeptide according to SEQ ID NO:1 or a polynucleotide encoding a Saxatilin polypeptide according to SEQ ID NO:2 in the preparation of a medicament for use in inhibiting metastatic tumor growth. 
 
     
 19. A cDNA according to claim 1, substantially as herein described with reference to any one of the examples or figures. 
 
     
 20. Saxatilin according to claim 2, substantially as herein described with reference to any one of the examples or figures. 
 
     
 21. A process according to claim 3, substantially as herein described with reference to any one of the examples or figures. 
 
     
 22. An agent according to claim 11, substantially as S 35 herein described with reference to any one of the examples or figures. H:\Simeona\Keep\Speci\61848.00.doc 14/11/03 27  
 
     
 23. An agent according to claim 12, substantially as herein described with reference to any one of the examples or figures. Dated this 14th day of November 2003 KWANG-HOE CHUNG and DOO-SIK KIM By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia H:\Simeona\Keep\Speci\61848.OO.doc 14/11/03 
 
   
 
 
 
 
 
 
 
 
